jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Listen now
Description
Known as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
More Episodes
Dr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in...
Published 06/07/24
Published 06/07/24
Researchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
Published 06/05/24